AstraZeneca Nasal Spray Vaccine for Covid Fizzles in Small, Early Trial
- Results from China, India suggested promise for nasal vaccine
- UK drug giant was seeking alternative immunization route
This article is for subscribers only.
AstraZeneca Plc’s ambitions for developing an easier formulation of its Covid-19 vaccine -- one that might help curb contagion as well -- suffered a setback Monday as the nasal spray failed in an early test.
The spray vaccine didn’t elicit a strong immune response in the nasal mucosa tissue or in the rest of the body of volunteers, according to researchers at the University of Oxford. Astra shares fell less than 1% in London.